As 2025 draws to a close, neuroscience stands at a pivotal crossroads between remarkable scientific leaps and sobering reality checks. This year brought headline‑making advances in neurology, psychiatry, sleep medicine, and epilepsy, while also reminding us of the unpredictability of clinical research. From our vantage point at Lumanity, we’ve seen undeniable momentum from FDA fast‑track designations and breakthrough therapies to high‑profile trial disappointments, even if progress came in uneven steps.

In this wrap‑up, the team spotlights a few of the most important developments in each major area of neuroscience — the newsmakers that shaped both scientific conversation and industry strategy in 2025.

Neurodegeneration

  1. FDA Fast Track for Biogen’s BIIB080 (Tau‑Targeting, Alzheimer’s) This designation signaled growing confidence in tau‑modifying approaches as a complement or alternative to amyloid‑targeted therapies, with potential to accelerate progress in a field long defined by incremental gains.
  2. Roche Advances Prasinezumab in Parkinson’s Disease Early Phase 3 data suggest clinical benefit when paired with symptomatic care in early Parkinson’s — a rare bright spot in the quest for disease‑modifying PD treatments.
  3. Spinogenix Expanded Access Program for ALS Treatment (SPG302) In addition to providing another option for patients, this program will generate real‑world safety and efficacy data, potentially speeding the path to full approval.t

Psychiatry

  1. Compass Pathways’ Phase 3 Milestone in Psilocybin for TRD The first pivotal study to show sustained benefit in treatment‑resistant depression marks a turning point for the credibility and regulatory viability of psychedelic‑based therapies.
  2. Beckley Psytech’s Rapid‑Acting BPL‑003 Data A single dose producing durable relief in TRD patients strengthens the case for novel serotonergic approaches to overcome limitations of existing antidepressants.
  3. Big Pharma Makes Moves in Psychedelics AbbVie acquired Gilgamesh Pharmaceuticals, a deal driven by the company’s lead asset, bretisilocin, a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser psychedelic in Phase 2 for MDD.
  4. Rise of Biomarker‑Informed Trial Design EEG, fMRI, and digital measures took center stage for patient stratification and signal detection, laying the groundwork for more precise, efficient psychiatric drug development.

Sleep Disorders

  1. Takeda’s Orexin Agonist Oveporexton (TAK‑861) in Narcolepsy Type 1 A first‑in‑class therapy aimed at restoring orexin signaling, targeting the root cause rather than symptoms, and potentially redefining the standard of care.
  2. Exploration of Dual Orexin Receptor Antagonists (DORAs) for Insomnia Early‑stage data hint at new options for patients resistant to traditional hypnotics.
  3. (Emerging Trend) A shift toward mechanistic therapies over purely symptomatic ones, mirroring a broader movement across neuroscience.

Epilepsy & Genetic Neurology

  1. Stoke Therapeutics’ STK‑001 (Dravet Syndrome) Breakthrough Therapy Designation designed to boost SCN1A protein production, has accelerated development and deepened FDA engagement.
  2. Xenon’s XEN1101 and Encoded Therapeutics’ Gene Regulation Programs XEN1101 entered Phase 3 trials for focal epilepsy, offering a novel Kv7 channel modulation approach, while Encoded advanced precision gene regulation technologies still in preclinical stages.
  3. Gene Therapy Development for Dravet Syndrome (Preclinical to Translational Stage) Multiple programs targeting SCN1A mutations progressed toward first‑in‑human testing, fueling renewed industry interest in licensing and partnerships as part of a long‑term “cure portfolio.”

What 2025 Reinforced

Across neuroscience, 2025 reinforced several encouraging truths alongside clear areas for continued focus:

  • Scientific understanding continues to deepen, but translational gaps remain a central risk
  • Innovative modalities are advancing, while blood–brain barrier delivery still constrains many approaches. Biomarkers are improving trial design and confidence, even as further validation is needed to fully support regulatory and payer decision-making
  • Above all, success increasingly depends on integration across biology, clinical development, evidence generation, access strategy, and real-world adoption

The companies that will lead the next wave aren’t just running trials; they’re building integrated, end‑to‑end strategies that turn scientific promise into market impact.